Vivet, Therapeutics

Vivet Therapeutics Presents Interim Data from its Phase 1/ 2 GATEWAY Trial for the Treatment of Wilson Disease at EASL Congress 2024

07.08.2025 - 18:04:35 | prnewswire.co.uk

Vivet Therapeutics United Kingdom United States of America France Italy

en | boerse | 67981684 |